Advanced Hematology Oncology PDX Tumor Biology Platforms for Drug Advancement, presented by Neal Goodwin, PhD, Vice President of Research Development
Champions Oncology has established an advanced PDX platform for modeling hematology oncology malignancies, including AML and ALL. The resource consists of leukaphresis AML and ALL clinical patient samples that are characterized for the ability to engraft into P1 study mice.
Additionally a resource for modeling define patient populations as they progress co-clinically has been created by collecting blasts from patients as they progress in the clinic.
Both approaches are advantageous with the leukaphresis resource allowing for modeling large numbers of study mice across an established panel of patient samples and the co-clinical resource for modeling defined patient cohorts co-clinically.